Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Total Current Liabilities (2016 - 2025)

Moleculin Biotech's Total Current Liabilities history spans 10 years, with the latest figure at $6.9 million for Q4 2025.

  • Quarterly results put Total Current Liabilities at $6.9 million for Q4 2025, up 27.9% from a year ago — trailing twelve months through Dec 2025 was $6.9 million (up 27.9% YoY), and the annual figure for FY2025 was $6.9 million, up 27.9%.
  • Total Current Liabilities for Q4 2025 was $6.9 million at Moleculin Biotech, up from $5.7 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $7.9 million in Q2 2025 to a low of $3.4 million in Q2 2021.
  • The 5-year median for Total Current Liabilities is $5.5 million (2024), against an average of $5.4 million.
  • The sharpest move saw Total Current Liabilities soared 74.9% in 2022, then tumbled 38.89% in 2023.
  • Year by year, Total Current Liabilities stood at $3.6 million in 2021, then skyrocketed by 33.05% to $4.8 million in 2022, then skyrocketed by 41.42% to $6.8 million in 2023, then dropped by 21.36% to $5.4 million in 2024, then grew by 27.9% to $6.9 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $6.9 million, $5.7 million, and $7.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.